Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

@article{Pfaller2007UseOF,
  title={Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.},
  author={Michael A. Pfaller and Shawn A. Messer and Linda B Boyken and Cassie L Rice and Shailesh Tendolkar and Richard J. Hollis and Daniel J. Diekema},
  journal={Journal of clinical microbiology},
  year={2007},
  volume={45 1},
  pages={70-5}
}
Clinical laboratories frequently face the problem of delayed availability of commercially prepared approved reagents for performing susceptibility testing of new antimicrobials. Although this problem is encountered more often with antibacterial agents, it is also an issue with antifungal agents. A current example is voriconazole, a new triazole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and other opportunistic fungal pathogens. The present study… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
38 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…